닥플 플러스
2026 International Congress of Diabetes and Metabolism(2일차)
대한당뇨병학회
연수평점 :6점
오프라인
주관
대한당뇨병학회
교육일자
2026-10-16
수강료
450,000원
교육형태
오프라인
등록일시
2026-08-06
교육시간
30시간 20분
연수평점
6점
장소
서울특별시 서울, 마곡코엑스(1층, 3층, 4층)
교육종류
내과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-10-16 | 08:00~08:15 | Evaluating and comparing CGM accuracy and reliability: insights from recent clinical trial | 김지윤(성균관의대 내과) | - |
| 2026-10-16 | 08:00~08:15 | Managing residual atherogenic dyslipidemia in patients with type 2 diabetes | 허지혜(한림의대 내과) | - |
| 2026-10-16 | 08:15~08:30 | Personalized diabetes management enabled by CGM and digital health solutions | 이준엽(가톨릭의대 내과) | - |
| 2026-10-16 | 08:15~08:30 | Ideal combination therapy for T2DM: SGLT-2i & TZD | 배재현(한림의대 내과) | - |
| 2026-10-16 | 08:30~09:00 | 휴식 | - | - |
| 2026-10-16 | 09:00~09:25 | Semaglutide and the new era of metabolic medicine: mechanisms, evidence, and future directions | Daniel J. Drucker(University of Toronto) | - |
| 2026-10-16 | 09:25~09:50 | Beyond the threat : achieving total metabolic and cardiovascular success with once-weekly semaglutide | Darren McGuire(University of Texas Southwestern Medical Center) | - |
| 2026-10-16 | 09:50~10:15 | Navigating the real-world patient journey: efficacy and tolerability of once-weekly semaglutide | Ryo Suzuki(Tokyo Medical University) | - |
| 2026-10-16 | 09:00~09:25 | GPR40 (FFAR1) as a therapeutic target in type 2 diabetes: mechanistic insights and clinical potential | 이용호(연세의대 내과) | - |
| 2026-10-16 | 09:25~09:50 | Targeting intestinal and renal glucose transport: the rationale and clinical implications of SGLT1/2 dual inhibitors | 이은영(가톨릭의대 내과) | - |
| 2026-10-16 | 09:50~10:15 | Novel therapeutics for muscle health: in the context of obesity and more | 전해민(한미약품) | - |
| 2026-10-16 | 09:00~09:20 | New insights into the molecular events that lead to MASLD. | Jay D. Horton(UT Southwestern School of Medicine USA) | - |
| 2026-10-16 | 09:20~09:40 | Metabolic–epigenomic coupling determines adipose plasticity and metabolic health | Juro Sakai(Tohoku University Japan) | - |
| 2026-10-16 | 09:40~10:00 | Targeting autophagy in infection and inflammation | 조은경(충남의대) | - |
| 2026-10-16 | 10:00~10:20 | Panel discussion | 이재민 임승순 정창화(DGIST 계명대학교 의과대학 한국식품연구원) | - |
| 2026-10-16 | 09:00~09:25 | Genetic architecture and heterogeneity in type 1 diabetes: from GWAS to functional insights | Stephen S. Rich(University of Virginia) | - |
| 2026-10-16 | 09:25~09:50 | Heterogeneity of diabetes in East Asians | Wayne H-H Sheu(National Health Research Institutes Taiwan) | - |
| 2026-10-16 | 09:50~10:15 | Genomic and multi-omic insights into the heterogeneity of diabetic kidney disease | 배재현(서울의대 내과) | - |
| 2026-10-16 | 09:00~09:20 | Practical screening and emotional coaching for diabetes distress | 나영(여의도성모병원 간호팀) | - |
| 2026-10-16 | 09:20~09:40 | Nutritional strategies: reducing diet-related distress | 임현정(경희대학교 의학영양과) | - |
| 2026-10-16 | 09:40~10:00 | Psychosocial interventions for diabetes distress: addressing psychosocial and environmental determinants | 이지현(강남세브란스병원 사회사업팀) | - |
| 2026-10-16 | 10:00~10:20 | Panel discussion | 김원준 장연정 김동철(울산의대 내과 세브란스병원 간호팀 인하대학교병원 당뇨비만센터) | - |
| 2026-10-16 | 09:00~09:20 | Gestational diabetes as a window into life-course diabetes risk | 곽수헌(서울의대 내과) | - |
| 2026-10-16 | 09:20~09:40 | Youth-onset diabetes in Korea: epidemiology and a national registry for prevention and care | 김재현(서울의대 소아청소년과) | - |
| 2026-10-16 | 09:40~10:00 | Toward optimal diabetes care in Korean older adults through evidence-based management strategies | 윤재승(가톨릭의대 내과) | - |
| 2026-10-16 | 10:00~10:20 | Panel discussion | 임주현 문준호 김지윤 정한나(국립보건연구원 서울의대 내과 성균관의대 내과 한림의대 내과) | - |
| 2026-10-16 | 10:20~10:30 | 휴식 | - | - |
| 2026-10-16 | 10:30~10:40 | Opening address | - | - |
| 2026-10-16 | 10:40~11:20 | Mitigating the consequences of hyperglycaemia in type 2 diabetes: lessons from the UKPDS | Rury R. Holman(University of Oxford UK) | - |
| 2026-10-16 | 11:20~12:00 | Answered prayers: the GLP-1 RA related medications provide efficacy beyond appetite and incretin effects | Donna Ryan(Pennington Biomedical Research Center USA) | - |
| 2026-10-16 | 12:00~12:10 | 휴식 | - | - |
| 2026-10-16 | 12:10~12:25 | The role of DPP-4 inhibitors in Korean diabetes care: focusing on k-evidence | 이용호(연세의대 내과) | - |
| 2026-10-16 | 12:10~12:25 | T2D management in the CKM Era: the role of combination therapy in glycemic control | 김수경(경상의대 내과) | - |
| 2026-10-16 | 12:10~12:25 | Does switching within the DPP-4 inhibitor class make a real difference?: integrating Korean RWE into diabetes care | 이지은(차의과학대 내과) | - |
| 2026-10-16 | 12:10~12:25 | Re-evaluation of glucose lowering effect in DPP4i | 이은영(가톨릭의대 내과) | - |
| 2026-10-16 | 12:25~12:40 | Importance of timely insulin initiation: optimizing glycemic control with 2nd generation basal insulin following GLP-1 RA treatment | 오태정(서울의대 내과) | - |
| 2026-10-16 | 12:25~12:40 | One pill, broader benefits: the early T2D journey | 김혜경(연세의대 내과) | - |
| 2026-10-16 | 12:25~12:40 | Beyond weight loss; advancing obesity management through efpeglenatide | 임수(서울의대 내과) | - |
| 2026-10-16 | 12:25~12:40 | Management of inadequately controlled patients with diabetes mellitus | 최덕현(순천향의대 내과) | - |
| 2026-10-16 | 12:40~13:40 | 점심식사 | - | - |
| 2026-10-16 | 13:40~14:05 | Restoring reproductive health: unexpected effects of incretin-based therapy on fertility and reproductive function | Mojca Jensterle(University Medical Centre Ljubljana Slovenia) | - |
| 2026-10-16 | 14:05~14:30 | Rewiring reward pathways: the impact of NUSH-based therapy on addiction and compulsive behaviors | 민세희(울산의대 내과) | - |
| 2026-10-16 | 14:30~14:55 | Beyond type 2 diabetes: emerging roles of NUSH-based therapy in type 1 diabetes | Viral N Shah(Indiana University USA) | - |
| 2026-10-16 | 13:40~14:00 | Overview of key revisions and the Korean evidence initiative | 배재현(서울의대 내과) | - |
| 2026-10-16 | 14:00~14:20 | Updating the T2D algorithm: weight-centric and CKM-oriented approaches | 김진화(조선의대 내과) | - |
| 2026-10-16 | 14:20~14:40 | Next-generation therapies for T2D with obesity | 오태정(서울의대 내과) | - |
| 2026-10-16 | 14:40~15:00 | Expanding CGM indications and digital health integration | 문선준(성균관의대 내과) | - |
| 2026-10-16 | 13:40~14:00 | Regulated necrosis in diabetes: ferroptosis in β-cell failure and complications | 고관표(제주의대 내과) | - |
| 2026-10-16 | 14:00~14:20 | Redox protein modification controls plasma membrane lipid peroxidation during ferroptosis | 이은우(KRIBB) | - |
| 2026-10-16 | 14:20~14:40 | Lysosomal lipid peroxidation triggers ferroptosis induction | Ken-ichi Yamada(Kyushu University) | - |
| 2026-10-16 | 14:40~15:00 | Panel discussion | 이윤희 이헌상 정수명(서울대 약대 고려대학교 생명과학부 성균관대학교 생명과학부) | - |
| 2026-10-16 | 13:40~14:05 | The metabolic landscape of cancer prognosis: an epidemiologic perspective | Sixten Harborg(Aarhus University Denmark) | - |
| 2026-10-16 | 14:05~14:30 | Hyperinsulinemia, inflammation, and cancer: mechanisms | 최연경(경북의대 내과) | - |
| 2026-10-16 | 14:30~14:55 | Impact of anti-diabetic agents on cancer risk: focusing on GLP-1 RA and SGLT2i | 정창희(울산의대 내과) | - |
| 2026-10-16 | 13:40~14:00 | Strategies to expand patient enrollment and strengthen the home healthcare pilot program | 곽효선 (대구가톨릭대학병원) | - |
| 2026-10-16 | 14:00~14:20 | Analyzing dropout factors and improving adherence in the home healthcare pilot program | 최영진 (강동경희대병원) | - |
| 2026-10-16 | 14:20~14:40 | Pancreatic disability registration: patient benefits, registration process, and real-world challenges | 구민정(서울대학교병원) | - |
| 2026-10-16 | 14:40~15:00 | Panel discussion | 진혜경 이혜미 김민경(단국대학교병원 삼성서울병원 서울아산병원) | - |
| 2026-10-16 | 13:40~13:55 | Understanding class effect and clinical variability in SGLT2 inhibition | 손장원(가톨릭의대 내과) | - |
| 2026-10-16 | 13:55~14:10 | SGLT2 Inhibition in Asian populations (Indonesia) | Soebagijo Adi Soelistijo(RSUD Dr. Soetomo Indonesia) | - |
| 2026-10-16 | 14:10~14:25 | Exploring a next-generation approach in SGLT2 inhibition based on Asian clinical evidence | 서다혜(인하의대 내과) | - |
| 2026-10-16 | 14:25~14:40 | Panel discussion | Nanny N.M. Soetedjo 전숙 서성환(Universitas Padjadjaran Indonesia 경희의대 내과 성균관의대 내과) | - |
| 2026-10-16 | 13:40~13:50 | Metabolic dysfunction-associated steatotic liver disease and all-cause and cause-specific mortality | 오로사(성균관의대 내과) | - |
| 2026-10-16 | 13:50~14:00 | Use of glucagon-like peptide-1 receptor agonists does not increase the risk of cancer in patients with type 2 diabetes mellitus | 김미진(부산의대 내과) | - |
| 2026-10-16 | 14:00~14:10 | Prevalence, incidence, and metabolic characteristics of young adults with type 2 diabetes mellitus in South Korea (2010–2020) | 김지윤(성균관의대 내과) | - |
| 2026-10-16 | 14:10~14:20 | Macrophage-specific progranulin deficiency prevents diet-induced obesity through the inhibition of hypothalamic and adipose tissue inflammation | 박채범(울산의대 내과) | - |
| 2026-10-16 | 14:20~14:30 | Ultra-processed food intake and risk of type 2 diabetes mellitus: a dose-response meta-analysis of prospective studies | 김유진(고려대 보건정책학과) | - |
| 2026-10-16 | 14:30~14:40 | Efficacy and safety of automated insulin delivery systems in patients with type 1 diabetes mellitus: a systematic review and meta-analysis | Wenqi Fan(The Second Xiangya Hospital of Central South University China) | - |
| 2026-10-16 | 14:40~16:00 | 휴식 | - | - |
| 2026-10-16 | 15:10~15:50 | Cellular senescence, diabetes, and complications of metabolic disease: the potential roles of senotherapies | James L. Kirkland(Cedars-Sinai Medical Center USA) | - |
| 2026-10-16 | 15:50~16:00 | 휴식 | - | - |
| 2026-10-16 | 16:00~16:25 | Expanding spectrum of complication of diabetes based on CKM concept | 임수(서울의대 내과) | - |
| 2026-10-16 | 16:25~16:50 | Interplay between MASLD and diabetes | Norbert Stefan(University Tübingen Germany) | - |
| 2026-10-16 | 16:50~17:15 | Diabetes and cognitive decline: focusing on neurodegeneration | 김희진(한양의대 신경과) | - |
| 2026-10-16 | 16:00~16:40 | Year in review and perspectives in the field of diabetes: clinical | 이은정(성균관의대 내과) | - |
| 2026-10-16 | 16:40~17:20 | From mechanisms to medicines: key discoveries in diabetes research 2026 | 고은희(울산의대 내과) | - |
| 2026-10-16 | 16:00~16:20 | CGM coverage and real-world uptake patterns in Korea: a national registry analysis | 김재현(성균관의대 내과) | - |
| 2026-10-16 | 16:20~16:40 | CGM standards and policy integration | Sof Andrikopoulos(Australian Diabetes Society Australia) | - |
| 2026-10-16 | 16:40~16:55 | Clinical implementation of CGM-linked lifestyle self-monitoring device | 이다영(고려의대 내과) | - |
| 2026-10-16 | 16:55~17:10 | Beyond glucose: AI transforming diabetes complications | Gaurav Puri(Metro South Health Australia) | - |
| 2026-10-16 | 17:10~17:20 | Panel discussion | 유승현 서지아(가톨릭관동의대 내과 고려의대 내과) | - |
| 2026-10-16 | 16:00~16:20 | Comparative analysis of DPN screening and diagnostic protocols across Asian guidelines: addressing resource-limited settings | Bin Lu(Fudan University) | - |
| 2026-10-16 | 16:20~16:40 | Defining the Asian phenotype: distinct clinical and pathogenetic characteristics of DPN in diverse Asian populations | 진흥용(전북의대 내과) | - |
| 2026-10-16 | 16:40~17:00 | Regional variations in pharmacological management of painful DPN: a review of first-line agents and access to novel therapies | Rayaz A Malik(Hamad Medical Center) | - |
| 2026-10-16 | 17:00~17:20 | Panel discussion | 오태정 윤지희 강선미(서울의대 내과 화순전남대학교병원 순천향의대 내과) | - |
| 2026-10-16 | 16:00~16:25 | Chrono-DM: the temporal dimension of prediabetes—linking sleep profiles, chronotype, and glycaemic control in Malaysian adults | Satvinder Kaur(UCSI University Kuala Lumpur Malaysia) | - |
| 2026-10-16 | 16:25~16:50 | AI-driven digital health platform for personalized nutrition: from CGM data to actionable insights | 김산(대상웰라이프) | - |
| 2026-10-16 | 16:50~17:15 | Tailored nutritional intervention: practical application of CGM-based glycemic data | 송윤주(가톨릭대학교 식품영양학과) | - |
| 2026-10-16 | 16:00~16:25 | The emerging role of nsMRA in CKM care | Hiddo Lambers Heerspink(University Medical Center Groningen) | - |
| 2026-10-16 | 16:25~16:50 | Scientific overview and clinical implication of Asian patients with finerenone | Daiji Kawanami(Fukuoka University) | - |
| 2026-10-16 | 16:50~17:15 | Bridging evidence and real world experience for cardio-renal protection | 조윤경(울산의대 내과) | - |
| 2026-10-16 | 16:00~16:20 | Global perspectives on reimbursement for advanced diabetes technology | 김준환(카카오헬스) | - |
| 2026-10-16 | 16:20~16:40 | Integrating diabetes technology into tertiary hospital evaluation: strategies for enhancing type 2 diabetes management quality | 최덕현(순천향의대 내과) | - |
| 2026-10-16 | 16:40~17:00 | Strategic revision of the general principles for antidiabetic medication reimbursement based on clinical practice guidelines | 강아름(부산의대 내과) | - |
| 2026-10-16 | 17:00~17:20 | Panel discussion | 강준혁 이진한 박상준 이지현 김선영(보건복지부 보험약제과 동아일보 순천향의대 내과 아주대학교병원 삼성서울병원) | - |
비고
Early bird 등록(2026년 8월 10일까지): 전문의(KDA 회원 240,000원 / 비회원 300,000원), 전공의·간호사·영양사·사회복지사·약사·연구원·운동처방사·관련 분야 교수 및 기타(KDA 회원 140,000원 / 비회원 200,000원)Advance 등록(2026년 9월 11일까지): 전문의(KDA 회원 280,000원 / 비회원 350,000원), 전공의 등(KDA 회원 180,000원 / 비회원 230,000원)현장등록(2026년 10월 15일~17일): 전문의(KDA 회원 370,000원 / 비회원 450,000원), 전공의 등(KDA 회원 250,000원 / 비회원 270,000원)
문의처
담당자
이연주
연락처
02-714-9071
이메일
diabetes@kams.or.kr